MedImmune upped by Thomas Weisel to outperform

MedImmune Inc. was upgraded by Thomas Weisel Partners analyst Ian Somaiya to outperform from peer perform on its amended marketing agreement for Synagis with Abbott Laboratories, which the firm also believes gives greater clarity regarding its drug NuMax. MedImmune shares Wednesday were down $0.20, or 0.67%, at $29.73 on volume of 5,935,425 shares versus the three-month running average of 1,717,220 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.